Mitomycin instillation to prevent recurrence of superficial bladder carcinoma. Results of a controlled, prospective study in 58 patients.

In a prospective randomized study, 58 patients with superficial bladder carcinoma received, after transurethral resection (TUR), either no further therapy (30 patients) or mitomycin at 20 mg/20 ml instilled every 2 weeks for the first year and every 4 weeks for the second year starting 3-4 weeks after TUR (28 patients). Bladder tumors recurred in only 2 patients in the treatment group; 15 patients in the control group had recurrences, with increases in grade in 4 patients and in stage in 6 patients. 3 patients in the control group developed metastases, including 1 who died of his tumor; there were no tumor-related deaths in the mitomycin group.

RCT Entities:   Population Interventions Outcomes